Title of article :
Nutritional Intervention in Chronic Fatigue Syndrome and Fibromyalgia (CFS/FMS) A Unique Porcine Serum Polypeptide Nutritional Supplement
Author/Authors :
Teitelbaum, Jacob Kona Research Center - Wellness Center - West, Vancouver, B.C., Pataskala, OH, USA , Morello, Gaetano Kona Research Center - Wellness Center - West, Vancouver, B.C., Pataskala, OH, USA , Goudie, Sarah Kona Research Center - Wellness Center - West, Vancouver, B.C., Pataskala, OH, USA
Pages :
7
From page :
52
To page :
58
Abstract :
Background: Clinical experience suggested that a unique porcine serum polypeptide extract, used in hospitals for people with severe malnutrition, serendipitously resulted in a dramatic improvement in many fibromyalgia cases. Aims: The study aims to determine the effectiveness of a unique polypeptide serum extract in improving the symptoms of CFS and fibromyalgia (CFS/FMS). Methods: An open-label prospective study of 43 people with CFS or Fibromyalgia recruited worldwide. Interventions: Four 500 mg tablets twice daily for five weeks. Outcome Measures: Assessed baseline at five weeks of treatment using a VAS(1-10 points) rating energy, sleep, cognitive function, pain, overall well-being, anxiety, and digestive health, as well as the FIQR. The primary outcome measure was the pre- and post-treatment VAS composite score for the first five symptoms. Results: 43 subjects completed the three-week treatment trial. 60.5% of subjects rated themselves as improved, with 18.6% rating themselves as much better. In the 60.5% of subjects that rated themselves as improved, the significant average improvement was seen in all categories: 1. 69.4% increase in energy(p<.001) 2. 69.2% increase in overall well-being(<.001) 3. 53.8% improvement in sleep(<.001) 4. 60.5% improvement in mental clarity(<.001) 5. 37.9% decrease in pain(<.013) 6. 34.8% decrease in anxiety(<.001) 7. 54.6% improvement in digestive symptoms(<.001) 8. FIQR 59.2 to 39.3(<.001) In six individuals who also had pre- and post IgG antibody levels, total IgG increased by 13.8% on average, with similar improvements seen in the IgG 1-4 subsets. Conclusion: Recovery Factors® resulted in markedly improved energy, sleep, cognition, pain relief, calming, digestion and overall well-being in those with CFS/FMS. Clinical Trial Registration Number: NCT04381793.
Farsi abstract :
فاقد چكيده فارسي
Keywords :
Fibromyalgia , Chronic fatigue syndrome , Polypeptides , Immune deficiency , Pain , Pain relief
Journal title :
Open Pain Journal
Serial Year :
2020
Full Text URL :
Record number :
2584392
Link To Document :
بازگشت